[funfunfun]

I could be lead to that conclusion, but I see this another way. Running the business of a multinational pharma company doesn't qualify you to judge primary literature in microbiology, methods, or data science of the results. It also doesn't help you differentiate claims from hot air in this emerging space. Considering the maturity of this field I think these are the skills required for due diligence. I think a pharma CEO as well as you and I are at the mercy of pop-sci reporting.

[refurb]

From what I read, he came by the board seat through his involvement with one of the VC that participated in this round.